Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 9/20 | 0.34 |
| ▸ | PDE5A | O76074 | 2/20 | 0.32 |
| ▸ | CNR1 | P21554 | 3/20 | 0.31 |
| ▸ | CNR2 | P34972 | 3/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | ABHD12 | Q8N2K0 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22105423 | 0.88 | P2RX3 (0.35) | P2RX3PDE5ACYP2D6HRH1 | |
| SCHEMBL24495690 | 0.86 | P2RX3 (0.34) | P2RX3PDE5ACNR1CNR2CYP2D6 | |
| SCHEMBL22105742 | 0.86 | P2RX3 (0.33) | P2RX3PDE5ACNR1CNR2CYP2D6 | |
| SCHEMBL22105849 | 0.85 | P2RX3 (0.35) | P2RX3PDE5ACYP2D6HRH1P2RX7 | |
| SCHEMBL22105422 | 0.82 | P2RX3 (0.37) | P2RX3P2RX7 | |
| SCHEMBL24091847 | 0.81 | P2RX3 (0.31) | P2RX3 | |
| SCHEMBL24495601 | 0.81 | P2RX3 (0.31) | P2RX3 | |
| SCHEMBL24091844 | 0.80 | P2RX3 (0.31) | P2RX3 | |
| SCHEMBL24092238 | 0.79 | P2RX3 (0.35) | P2RX3CYP2D6HRH1 | |
| SCHEMBL22105355 | 0.78 | PDE5A (0.43) | P2RX3PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200190093-A1 | SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190093-A1 | SUBSTITUTED XANTHINE DERIVATIVES | TRPC5, TRPC4, TRPM5 | P2RX3 9/4885PDE5A 468/4885CNR1 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.